Ani Pharma Drug Patent Portfolio
Ani Pharma owns 5 orange book drugs protected by 16 US patents with Innopran Xl having the least patent protection, holding only 1 patent. And Veregen with maximum patent protection, holding 5 patents. Given below is the list of Ani Pharma's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11975047 | Methods for storing and warming purified corticotropin compositions | 27 Oct, 2043 | Active |
| US12102662 | Methods for storing and warming purified corticotropin compositions | 27 Oct, 2043 | Active |
| US12233105 | Methods for storing and warming purified corticotropin compositions | 27 Oct, 2043 | Active |
| US12324787 | Contactless optical process for identifying objects | 27 Oct, 2043 | Active |
| US12440542 | 27 Oct, 2043 | Active | |
| US7858662 | Medicament for the treatment of viral skin and tumour diseases | 02 Oct, 2026 | Active |
| US9770406 | Medicament for the treatment of viral skin and tumour diseases | 12 Jul, 2025 | Expired |
| US10434059 | Medicament for the treatment of viral skin and tumour diseases | 18 Nov, 2022 | Expired |
| US6500454 | Timed, sustained release systems for propranolol | 04 Oct, 2021 | Expired |
| US5795911 | Composition for treating Condyloma acuminata | 31 Oct, 2020 | Expired |
| US5968973 | Method for treating hyperplasia | 10 Apr, 2017 | Expired |
| US5721263 | Pharmaceutical composition for angiotensin II-mediated diseases | 24 Feb, 2015 | Expired |
| US5958961 | Pharmaceutical composition for angiotensin II-mediated diseases | 06 Jun, 2014 | Expired |
| US5534534 | Pharmaceutical compositions for oral use and method of preparing them | 09 Jan, 2014 | Expired |
| US5534534 | Pharmaceutical compositions for oral use and method of preparing them | 09 Jul, 2013 | Expired |
| US5196444 | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof | 04 Dec, 2012 | Expired |
Latest Legal Activities on Ani Pharma's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Ani Pharma.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Information Disclosure Statement considered | 04 Sep, 2025 | US12440542 |
| Date Forwarded to Examiner | 28 Aug, 2025 | US12440542 |
| track 1 ON | 28 Aug, 2025 | US12440542 |
| Response after Non-Final Action | 18 Aug, 2025 | US12440542 |
| PARALEGAL OR ELECTRONIC TERMINAL DISCLAIMER APPROVED | 18 Aug, 2025 | US12440542 |
| Terminal Disclaimer Filed | 18 Aug, 2025 | US12440542 |
| Electronic Review | 16 Jul, 2025 | US12440542 |
| Email Notification | 16 Jul, 2025 | US12440542 |
| Mail Non-Final Rejection | 16 Jul, 2025 | US12440542 |
| Non-Final Rejection | 12 Jul, 2025 | US12440542 |
| Information Disclosure Statement considered | 12 Jul, 2025 | US12440542 |
| Case Docketed to Examiner in GAU | 29 Jun, 2025 | US12440542 |
| Track 1 Request Granted | 23 Jun, 2025 | US12440542 |
| Case Docketed to Examiner in GAU | 19 Jun, 2025 | US12440542 |
| Application Dispatched from OIPE | 19 Jun, 2025 | US12440542 |
Ani Pharma's Drug Patent Litigations
Ani Pharma's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Sep 08, 2015, against patent number US9770406. The petitioner , challenged the validity of this patent, with Yunik Chang et al as the respondent. Click below to track the latest information on how companies are challenging Ani Pharma's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US9770406 | September, 2015 |
Decision
(07 Feb, 2017)
| Yunik Chang et al | |
Ani Pharma's Family Patents
Recent FDA approvals and tentative approvals for Ani Pharma
This section lists recent FDA approvals and tentative approvals for Lupin, covering innovator and generic drugs with key regulatory details and timelines.
Generic drugs
Includes generic drug submissions with tentative FDA approvals, not yet marketable due to patent or exclusivity restrictions.
| Drug Name | Submission class (FDA) | Submission Category | Submission Date |
|---|---|---|---|
| Memantine Hydrochloride And Donepezil Hydrochloride |
ORIG-2
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | - | 15 Dec, 2023 |
Ani Pharma Drug List
Given below is the complete list of Ani Pharma's drugs and the patents protecting them.
1. Atacand
Atacand is protected by 3 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5534534
(Pediatric)
| Pharmaceutical compositions for oral use and method of preparing them |
09 Jan, 2014
(12 years ago)
| Expired |
| US5534534 | Pharmaceutical compositions for oral use and method of preparing them |
09 Jul, 2013
(12 years ago)
| Expired |
| US5196444
(Pediatric)
| 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
04 Dec, 2012
(13 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Atacand's drug page
2. Atacand Hct
Atacand Hct is protected by 5 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5721263 | Pharmaceutical composition for angiotensin II-mediated diseases |
24 Feb, 2015
(11 years ago)
| Expired |
| US5958961 | Pharmaceutical composition for angiotensin II-mediated diseases |
06 Jun, 2014
(11 years ago)
| Expired |
| US5534534
(Pediatric)
| Pharmaceutical compositions for oral use and method of preparing them |
09 Jan, 2014
(12 years ago)
| Expired |
| US5534534 | Pharmaceutical compositions for oral use and method of preparing them |
09 Jul, 2013
(12 years ago)
| Expired |
| US5196444
(Pediatric)
| 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
04 Dec, 2012
(13 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Atacand Hct's drug page
3. Innopran Xl
Innopran Xl is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6500454 | Timed, sustained release systems for propranolol |
04 Oct, 2021
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Innopran Xl's drug page
4. Purified Cortrophin Gel
Purified Cortrophin Gel is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11975047 | Methods for storing and warming purified corticotropin compositions |
27 Oct, 2043
(17 years from now)
| Active |
| US12102662 | Methods for storing and warming purified corticotropin compositions |
27 Oct, 2043
(17 years from now)
| Active |
| US12233105 | Methods for storing and warming purified corticotropin compositions |
27 Oct, 2043
(17 years from now)
| Active |
| US12324787 | Contactless optical process for identifying objects |
27 Oct, 2043
(17 years from now)
| Active |
| US12440542 |
27 Oct, 2043
(17 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Purified Cortrophin Gel's drug page
5. Veregen
Veregen is protected by 5 patents, out of which 4 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7858662 | Medicament for the treatment of viral skin and tumour diseases |
02 Oct, 2026
(6 months from now)
| Active |
| US9770406 | Medicament for the treatment of viral skin and tumour diseases |
12 Jul, 2025
(8 months ago)
| Expired |
| US10434059 | Medicament for the treatment of viral skin and tumour diseases |
18 Nov, 2022
(3 years ago)
| Expired |
| US5795911 | Composition for treating Condyloma acuminata |
31 Oct, 2020
(5 years ago)
| Expired |
| US5968973 | Method for treating hyperplasia |
10 Apr, 2017
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Veregen's drug page